RT Journal Article
SR Electronic
T1 D614G Spike Variant Does Not Alter IgG, IgM, or IgA Spike Seroassay Performance
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.08.20147371
DO 10.1101/2020.07.08.20147371
A1 Klumpp-Thomas, Carleen
A1 Kalish, Heather
A1 Hicks, Jennifer
A1 Mehalko, Jennifer
A1 Drew, Matthew
A1 Memoli, Matthew J
A1 Hall, Matthew D
A1 Esposito, Dominic
A1 Sadtler, Kaitlyn
YR 2020
UL http://medrxiv.org/content/early/2020/07/10/2020.07.08.20147371.abstract
AB Emergence of a new variant of spike protein (D614G) with increased infectivity and transmissibility has prompted many to analyze the potential role of this variant in the SARS-CoV-2 pandemic. When a new variant emerges, there is a concern regarding whether an individual exposed to one variant of a virus will have cross-reactive immune memory to the second variant. Accordingly, we analyzed the serologic reactivity of D614 (original) and G614 variant spike proteins. We found that antibodies from a high-incidence population in New York City reacted both toward the original D614 spike and the G614 spike variant. These data suggest that patients who have been exposed to either SARS-CoV-2 variant have humoral immunity that can respond against both variants. This is an important finding both for SARS-CoV-2 disease biology and for potential antibody-based therapeutics.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study utilizes de-identified samples from a pre-existing NIH clinical study NCT01386424 as archival (pre-pandemic) control samples.Funding StatementThis research was supported in part by the Intramural Research Program of the NIH, including the National Institute of Biomedical Imaging and Bioengineering, the National Institute of Allergy and Infectious Disease, and the National Center for Advancing Translational Sciences. This project has been funded in part with Federal funds from the National Cancer Institute, National Institutes of Health, under contract number HHSN261200800001E. Disclaimer: The NIH, its officers, and employees do not recommend or endorse any company, product, or service.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The negative controls were collected under an approved NIH protocol listed on ClinicalTrials.gov NCT01386424. All other samples used were uncoded, deidentified samples collected with local IRB approval and determined to be IRB exempt by the NIH IRB for us to receive and use for this analysis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data are available from the authors upon request.